anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
BACKGROUND: By interacting with bone marrow mesenchymal stem cells (BMSCs) and regulating their function through exosomes, bone macrophages play crucial roles in various bone-related diseases. Research has highlighted a notable increase in the number of M1 macrophages in glucocorticoid-associated osteonecrosis of the femoral head (GA-ONFH). Nevertheless, the intricate crosstalk between M1 macrophages and BMSCs in the glucocorticoid-stimulated environment has not been fully elucidated, and the underlying regulatory mechanisms involved in the occurrence of GA-ONFH remain unclear.
METHODS: We employed in vivo mouse models and clinical samples from GA-ONFH patients to investigate the interactions between M1 macrophages and BMSCs. Immunofluorescence staining was used to assess the colocalization of M1 macrophages and BMSCs. Flow cytometry and transcriptomic analysis were performed to evaluate the impact of exosomes derived from normal (n-M1) and glucocorticoid-stimulated M1 macrophages (GC-M1) on BMSC differentiation. Additionally, miR-1a-3p expression was altered in vitro and in vivo to assess its role in regulating adipogenic differentiation.
RESULTS: In vivo, the colocalization of M1 macrophages and BMSCs was observed, and an increase in M1 macrophage numbers and a decrease in bone repair capabilities were further confirmed in both GA-ONFH patients and mouse models. Both n-M1 and GC-M1 were identified as contributors to the inhibition of osteogenic differentiation in BMSCs to a certain extent via exosome secretion. More importantly, exosomes derived from GC-M1 macrophages exhibited a heightened capacity to regulate the adipogenic differentiation of BMSCs, which was mediated by miR-1a-3p. In vivo and in vitro, miR-1a-3p promoted the adipogenic differentiation of BMSCs by targeting Cebpz and played an important role in the onset and progression of GA-ONFH.
CONCLUSION: We demonstrated that exosomes derived from GC-M1 macrophages disrupt the balance between osteogenic and adipogenic differentiation in BMSCs, contributing to the pathogenesis of GA-ONFH. Inhibiting miR-1a-3p expression, both in vitro and in vivo, significantly mitigates the preferential adipogenic differentiation of BMSCs, thus slowing the progression of GA-ONFH. These findings provide new insights into the regulatory mechanisms underlying GA-ONFH and highlight potential therapeutic targets for intervention.
Despite increasing knowledge on the pathophysiology of cardio-vascular diseases (in particular the role of inflammation in the development of atherosclerosis), predicting their occurrence remains largely difficult. Aging remains the most powerful factor for predicting the occurrence of myocardial infarction, independently from other identified risk factors. Few years ago, acquired mutations were described in the hematopoietic system of apparently healthy subjects. This phenomenon, now described as CHIP (Clonal Hematopoiesis of Indeterminate Potential) is more frequently observed in elderly people, and has been recently linked to an increased risk of cardio-vascular events. Experiments in mice demonstrated that these CHIPs are responsible for an inflammation that supports the development of atherosclerosis. However the link between CHIP, inflammation and atherosclerosis has never been demonstrated in humans.

In this study, the investigators will search for an increased frequency of CHIP in patients with a first cardio-vascular event (CVE). Seven months after the CVE, a blood sample will be taken. Mutations in the 9 most frequently mutated genes in CHIP will be evaluated by Next Generation Sequencing. Systemic inflammation will be evaluated by measurement of circulating levels of CRP, IL-1β, IL-6, IL-10 and TNF-α. Atherosclerosis will be evaluated via the volume of atherosclerotic plaques as assessed by 3D ultrasound analysis. The presence of CHIP will be correlated to traditional cardiovascular risk factors, systemic inflammation markers and the level of atherosclerosis. The investigators will also assess the relationship between the presence of CHIP and the risk of CVE reoccurrence.
Regimen will be the same with additional dexmedetomidine infusion: with loading dose: 0.5 µg/kg/h through 1 hour and then dose will be reduced to 0.25 µg/kg/h and infusion will be continued during surgery and postoperative period to the total dose of 200 µg. Anesthetics and opioids doses will be adjusted under hemodynamic and eeg sensor - SedLine Masimo.
MnSOD PL (0.3, 3, or 30 mg) + (Paclitaxel + Carboplatin (45mg/m\^2)) + Radiation 1.9-2.1 Gy daily 5 times per week (4-6 hr after the first MnSOD PL dose). The total dose planned at 77.0 Gy with a range of 69-84Gy in 34-38 fractions over 7-8 weeks.
An electronic smart syringe is disclosed. The electronic smart syringe includes a barrel. The barrel includes a slot on a proximal end. The electronic smart syringe also includes a needle coupled on a distal end of the barrel. The electronic smart syringe further includes a plunger coupled on the proximal end of the barrel via the slot. The electronic smart syringe further includes a cartridge secured within the barrel and coupled with the plunger. The cartridge is configured to expel, via the needle, a prescribed dosage of a drug in the body of a patient. The electronic smart syringe further includes a biometric access panel operatively coupled with the plunger. The biometric access panel is configured to authenticate an authorized user for expelling the drug upon receiving one or more fingerprints. Electronic Smart syringe includes a flexible display unit and synchronized to the external end user computing device.
The present invention provides a neutron moderator that moderates neutrons, the neutron moderator comprising: a first intermediate layered body in which a plurality of disc-shaped magnesium fluoride sintered compacts are layered; and a second intermediate layered body in which the disc-shaped magnesium fluoride sintered compacts are layered, the second intermediate layered body being layered on the first intermediate layered body and including: a hole in the disc-shaped magnesium fluoride sintered compacts; a tapered surface surrounding the hole; a bottom surface; and a vertical inner wall disposed in a disc-shaped magnesium fluoride sintered compact disposed in a bottom of the second intermediate layered body , the vertical inner wall extending in a vertical direction through the tapered surface and the bottom surface of the disc-shaped magnesium fluoride sintered compact. The top surface 2A of the first intermediate layered body 2 and the bottom surface 3B of the second intermediate layered body 3 are joined together at the neutron moderator assembling process. The top surface 3A of the second intermediate layered body 3 becomes the top surface 1A of the neutron moderator. In addition, the bottom surface 2B of the first intermediate layered body 2 and the top surface 4A of the third intermediate layered body 4 are joined together. The bottom surface 4B of the third intermediate layered body 4 becomes the bottom surface 1B of the neutron moderator. The neutron moderator 1 is manufactured by layering the first intermediate layered body 2, the second intermediate layered body 3, and the third intermediate layered body 4.
The injection volume will be up to 5 mL over 20 seconds with an activity of 10 MBq/kg body weight (range between min. 500 and max. 800 MBq). To ensure application of the complete activity additionally 10 mL of 0.9% saline will be infused via the same system.
NEW MATERIAL:A triazinone compound shown by formula I (R1 is H or 1-4C alkyl; R2 is heterocyclyl-substituted 1-10C alkyl; Q is O or S; A is 1-4C alkylene; n is 1 or 2) and a salt thereof. EXAMPLE:4,5-Dihydro-6-(p-hydroxyphenyl)-1,2,4-triazin-3(2H)-one. USE:Showing improved inhibitory action on blood platelet aggregation and useful as an antihypertensive agent and a remedy for thrombotic embolism. Having high durability. Further useful as an intermediate for synthesizing an active compound. PREPARATION:For example, as shown in the reaction formula, a compound shown by formula II is reacted with hydrazine to give a compound shown by formula III, which is reacted with a compound shown by the formula X-A- COOR4 (R4 is H, etc.,; X is halogen) in the presence of a base to give a compound shown by formula IV. Then, this compound is reacted with an amine derivative shown by formula H-(NH)n-R2 to give a compound shown by formula I.
Described is a method for determining whether a treatment is effective in changing the status of a certain set of target cells, such as tumour cells, in a patient. This method comprises determining whether a sample contains an expression product of at least one marker gene from the patient after initiation of a treatment. Preferably, the sample is a blood sample. In one aspect, the expression product is expressed by a peripheral blood mononuclear cell. The marker gene may be a gene involved in the generation, maintenance and/or breakdown of blood vessels (angiogenesis). The method is suitable for determining whether a certain treatment against Kaposi's Sarcoma is being successful. Moreover, this method is suitable for determining the presence of angiogenesis and/or tumour cells in a patient.
Depression is a complex illness that impacts an individual's thoughts, behavior, mood, and physical health. Research has shown that many Asian Americans with depression do not complain about their symptoms or seek treatment, which has lead to an under-recognition of depression in this population. Furthermore, even when a primary care physician does diagnose depression in an Asian American, adequate treatment does not often follow. There is a clear need to understand the cultural reasons for why treatment is not sought out by Asian Americans. There is also a need for developing new treatments that specifically target the Asian American population. Offering culturally sensitive therapies combined with traditional medical care may make depressed Asian Americans more comfortable in seeking treatment for their illness. Culturally Sensitive Collaborative Treatment (CSCT) is a comprehensive approach to treating depression. It incorporates consultation with a culturally trained psychiatrist, medical treatment provided by a primary care provider, and care management provided by a bilingual and bicultural care manager. The purpose of this study is to evaluate the effectiveness of CSCT versus traditional medical care for the treatment of depression in Chinese Americans.

This 24-week study will enroll depressed Chinese Americans. Potential participants will be interviewed in primary care clinics to screen for depression. Once enrolled, all participants will attend a consultation with a psychiatrist trained in cultural sensitivity to introduce the concept and treatment of depression. Participants will then be randomly assigned to either CSCT or standard care. Both groups of participants will receive regular care from their primary care provider, but the CSCT group will also meet with a bilingual and bicultural care manager to learn how to fully manage their depression. Outcome measurements will include symptoms of depression; adherence to appointments with primary care providers; adherence to medication treatment; and adverse events. All measurements will be assessed during follow-up phone calls at Weeks 2, 6, 10, 14, 18, 22, and 24.
Participants allocated to this group will watch a 3-minute video presenting a series of control pictures of tourist attractions in London. An audio of a young adult describing herself visiting these sites during a trip will be played.
Starting dose 6 mg/m\^2 Decitabine intravenous (IV) over 1 hour on days 1-5 and 8-12 of weeks 1 and 2 (course 1). Week 3, Iodine I 131 (131I) scanning using thyrotropin alfa injections. Participants whose scan do not demonstrate iodine uptake continue suppressive thyroid hormone therapy but no further study therapy; these participants who do show uptake undergo thyroid hormone withdrawal on weeks 4-8 and second course of decitabine (as in course 1) on weeks 7 and 8, with 131I therapy on week 9.
The purpose of this study is to determine if music therapy services can serve as a viable, necessary, and beneficial aspect of inpatient pain management, distraction, and coping for pediatric patients in the acute care hospital setting. The investigator will note the effect of music therapy services in conjunction with pain scores reported by the participant and an increase in self and family reported coping skills during hospitalization.

Participants will be referred by providers from pain management service, oncology/hematology service, or the gastrointestinal (GI) service for functional and abdominal pain. Participants who meet the criteria for inclusion will be selected. The study will be explained to parents and a consent form will be left for the family to review and sign at their convenience. Participants will provide a pain scale level and vitals before completing the music therapy intervention. Once the music therapy intervention is completed, the pain scale and vitals will be repeated.
PURPOSE: Urinary sepsis is the leading cause of mortality in the setting of endourological procedures for stone treatment such as URS and PCNL; renal stones themselves may be a source of infection. Aim of this study is to determine the diagnostic accuracy of stone cultures (SC) collected during URS and PCNL in predicting post-operative septic complications, compared to preoperative bladder urine culture (BUC).
METHODS: We performed a systematic review (SR) of literature according to the PRISMA guidelines; Literature quality was evaluated according to The Risk Of Bias In Non-randomized Studies-of Interventions (ROBINS-I) assessment tool. A univariate meta-analysis (MA) was used to estimate pooled log odds ratio of BUC and SC, respectively.
RESULTS: Overall, 14 studies including 3646 patients met the inclusion criteria. Eight studies reported data from PCNL only; three from URS only; three from both URS and PCNL. Stone cultures showed a higher sensitivity (0.52 vs 0.32) and higher positive predictive value (0.28 vs 0.21) in predicting post-operative sepsis, compared to bladder urine cultures. The pool-weighted logarithmic odd risk (LOR) for BUC was 2.30 (95% CI 1.51-3.49, p < 0.001); the LOR for stone cultures (SC) in predicting post-operative sepsis was 5.79 (95% CI 3.58-9.38, p < 0.001).
CONCLUSION: The evidence from this SR and MA suggests that intraoperative SC from stone fragments retrieved during endourological procedures are better predictors of the likelihood of occurrence of post-operative sepsis compared to pre-operative BUC. Therefore, SC should be a standard of care in patients undergoing endourological interventions.
<P>PROBLEM TO BE SOLVED: To provide a system for producing a hematopoietic cell from human embryonic stem cells.  <P>SOLUTION: Differentiation is conducted in the presence of hematogenic cytokines and other factors. The cell population that is obtained is remarkably enriched in CD45+ve cells, a marker of early hematopoietic precursor with self-renewing capacity. Including a bone morphogenic protein during the differentiation process enhances the ability of the cell population to form secondary colonies. Because of the enormous replicative capacity of embryonic stem cells, this provides an important new commercial source of hematopoietic cells.  <P>COPYRIGHT: (C)2010,JPO&INPIT
The invention discloses cream for treating chilblain and a preparation method for the cream. The cream comprises the following traditional Chinese medicine extracts in parts by weight: 9-11 parts of a Chinese angelica extract, 4-6 parts of a radix glycyrrhizae extract, 5-8 parts of a caulis akebiae extract, 2-4 parts of a fructus evodiae extract, 10-15 parts of an astragalus extract, 3-8 parts of a garden balsam stem extract, further comprises 20-25 parts of an oil lubricating agent, 10-20 parts of gelatin and 5-10 parts of purified water. The preparation method for the cream comprises the following steps: (1) preparing the extract of each traditional Chinese medicine; (2) preparing sol; (3) preparing ointment; (4) bottling. A method of combining alcohol extraction and water extraction is used to extract the traditional Chinese medicine extracts, so that the extraction efficiency is high and purity of the extract is relatively high. The cream prepared from the traditional Chinese medicine extract can be used for curing the chilblain without a relapse, is free of side effect, quick in effect-taking, and can be used for effectively preventing the chilblain. Various traditional Chinese medicine raw materials in the cream are traditional Chinese medicine materials with relatively low price, so that the material cost is low.
Patients will be treated with doxorubicin and APX005M in 21 day cycles. All patients receive the same treatment (there is no "placebo" arm). After completing 8 cycles of study treatment, patients without evidence of disease progression or unacceptable toxicity may continue treatment with APX005M alone. Doxorubicin will not be continued beyond cycle 8 due to the risk for cardiac toxicity from cumulative dosing.
The invention relates to a Chinese herbal medicine composition with an aging resisting effect. The composition is characterized in that the composition comprises water and/or solvent extracts of the raw materials of, by weight: 30-70 pars of Siberian solomonseal rhizome, 30-70 parts of fragrant solomonseal rhizome, and 0.01-5 parts of gold foil. The solvent is selected from one or a combination of methanol, ethanol, isopropanol, n-butanol, ethylene glycol, 1,2-propanediol, 1,3-propanediol, 1,3-butanediol, acetone, and ethyl acetate. The Chinese herbal medicine extract and the Chinese herbal medicine composition comprising the extract have functions of skin moisturizing, repairing, protecting, tissue regenerating, and the like. The extract and the composition cause no irritation to skins, and can be directly used on skins for resisting aging. The extract and the composition can also be added into cosmetics as a functional additive. The cost of the extract or the composition is low.
BACKGROUND: Patients with brain injury who are unresponsive to commands may perform cognitive tasks that are detected on functional magnetic resonance imaging (fMRI) and electroencephalography (EEG). This phenomenon, known as cognitive motor dissociation, has not been systematically studied in a large cohort of persons with disorders of consciousness.
METHODS: In this prospective cohort study conducted at six international centers, we collected clinical, behavioral, and task-based fMRI and EEG data from a convenience sample of 353 adults with disorders of consciousness. We assessed the response to commands on task-based fMRI or EEG in participants without an observable response to verbal commands (i.e., those with a behavioral diagnosis of coma, vegetative state, or minimally conscious state-minus) and in participants with an observable response to verbal commands. The presence or absence of an observable response to commands was assessed with the use of the Coma Recovery Scale-Revised (CRS-R).
RESULTS: Data from fMRI only or EEG only were available for 65% of the participants, and data from both fMRI and EEG were available for 35%. The median age of the participants was 37.9 years, the median time between brain injury and assessment with the CRS-R was 7.9 months (25% of the participants were assessed with the CRS-R within 28 days after injury), and brain trauma was an etiologic factor in 50%. We detected cognitive motor dissociation in 60 of the 241 participants (25%) without an observable response to commands, of whom 11 had been assessed with the use of fMRI only, 13 with the use of EEG only, and 36 with the use of both techniques. Cognitive motor dissociation was associated with younger age, longer time since injury, and brain trauma as an etiologic factor. In contrast, responses on task-based fMRI or EEG occurred in 43 of 112 participants (38%) with an observable response to verbal commands.
CONCLUSIONS: Approximately one in four participants without an observable response to commands performed a cognitive task on fMRI or EEG as compared with one in three participants with an observable response to commands. (Funded by the James S. McDonnell Foundation and others.).
Patients diagnosed with thoracolumbar vsOVCFs in hospital and undergoing minimally invasive treatment from November 2019 to March 2021 were enrolled for the study. They were randomly allocated into two groups (based on random numbers generated by www. randomizer.org), namely PVP group and PVDP group.

Operative technique：In PVDP group, PVP and PCD both used a unilateral transpedicular approach into the vertebrae and disc. . Under general anesthesia, the patient was turned over to a prone position, and the deformity is reduced with a slight closed manipulative. Firstly, under fluoroscopic O-arm guidance, the puncture site was localized into the junction made by the transverse process and the superior articular process and entered the target area according to the puncture angle and depth measured before the operation. Secondly, the other puncture cannula was inserted into the intervertebral disc space adjacent to the ruptured endplate through the transpedicular access, and the target area was the middle of the intervertebral space. Thin-cut CT images were obtained intraoperatively by the O-arm fluoroscopy to confirm puncture needle placement location. Third, the bone cement was injected into the vertebrae and the intervertebral disc space, meanwhile, the cannula was also needed to move back to the vertebrae, and the bone cement in the vertebrae could connect the intervertebral disc space and the vertebrae to form a whole. Finally, the PVP group and the adjacent vertebrae performed by prophylactic vertebroplasty used bilateral pedicle puncture, under the guidance of the O-arm, two puncture needles were percutaneously inserted into the vertebrae, reaching about the middle of the vertebrae. Then, cement was slowly injected into the vertebral body, once cement leakage into the spinal canal or veins was detected, the injection was stopped.

The investigators measured radiological parameters including the local kyphotic angle (LKA), disc height anterior (DHA), and disc height posterior (DHP) from lateral plain radiographs preoperatively and at 1 day and final follow-up after surgery. The visual analog score (VAS) was used to assess the preoperative and postoperative back pain relief. The Oswestry Disability Index (ODI) was used to assess the quality of life and was recorded preoperatively, postoperatively, and final follow-up.